Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)

Impatients

Status

Conditions: Graft Vs Host Disease; Steroid Refractory Acute Graft Versus Host Disease; Acute-graft-versus-host Disease; Alpha-1 Proteinase Inhibitor; Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant; Alpha-1 Protease Inhibitor Deficiency; Alpha 1-Antitrypsin Deficiency; Graft-versus-host-disease

Treatments: Drug: Glassia

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT03172455

2017-AATGLAKAM-EU

Details and patient eligibility

About

An Early Access Program for patients with steroid refractory acute GvHD after hematopoietic stem cell transplantation.

This Program is available for female and male who are recipients of allogenic HSCT and who have been newly diagnosed with acute GvHD.

Full description

GLASSIA (human alpha-1 proteinase inhibitor (A1PI), also known as human alpha-1 antitrypsin, Kamada-AAT or Kamada-API) is a, liquid, ready-to-use preparation of human A1PI. Alpha-1 proteinase inhibitor belongs to the family of serine proteinase inhibitors and is primarily produced in the liver and secreted into the circulation. In addition to its anti-proteinase activity, A1PI showed to have anti-inflammatory, anti-apoptotic and immunomodulatory properties (1-4).

GLASSIA is an injection solution prepared from human plasma collected from healthy volunteer blood donors in accordance with Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulations. GLASSIA was approved in the United States (US) in July 2010 and is indicated for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe hereditary deficiency of Alpha1-PI (alpha1-antitrypsin deficiency).

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• This program is available for patients who suffer from steroid refractory acute GvHD after HSCT, or for whom, in the opinion of their treating physician, other treatment options or clinical trials in this indication are unsuitable.
• The disease indication for which the participant required HSCT must be in remission
• Acute graft-versus-host disease (aGvHD), including lower GI involvement (modified
• International Bone Marrow Transplant Registry (IBMTR) Severity Stage 1 to 4 [>500 mL diarrhea/day]), with or without other organ system involvement.
• For women of childbearing potential, had a negative serum or urine pregnancy test within 14 days prior to enrolment.

Exclusion criteria

• Participant with manifestations of chronic GvHD
• Participant with acute/chronic GvHD overlap syndrome
• Participant whose GvHD developed after donor lymphocyte infusion
• Participant with severe sepsis involving at least 1 organ failure
• Participant who is seropositive or positive in the nucleic acid test for human immunodeficiency virus (HIV)
• Participant with active hepatitis B or C
• If female, participant is pregnant or lactating at the time of enrollment, or has plans to become pregnant during the program